Introduction
Cholesterol accumulation is an increasing cause for cardiovascular diseases and is currently the major cause of morbidity and mortality. Due the change in lifestyle leading to cholesterol-related diseases such as, atherosclerosis, non-insulin dependent diabetes, obesity, myocardial infarction and coronary heart disease.
ApoB-100 (Apolipoprotein B-100) is part of very-low-density lipoprotein (VLDL), intermediatedensity lipoprotein (IDL) and LDL, and it functions as a transporter of cholesterol and triacylglycerols to cells throughout the body [8] . The assembly and secretion of ApoB-containing lipoproteins within the endoplasmic reticulum is strictly dependent on the microsomal trigylceride transfer protein (MTP) which shuttles triglycerides onto the nascent lipoprotein particle [6] . Sequence analysis showed that the amino-terminal 700 amino acids of vitellogenin Vtg and apolipoprotein (apo) B-100 are homologous, although the similarity is limited. Coincidentally, Vtg also binds lipids and transports them into the oocytes. The sequence and functional relationship of these two proteins support the idea that they have a common ancestor [2] . Like ApoB-100, vitellogenin binds hydrophobic molecules such as phospholipids, triacylglycerols and cholesterol and it transports these molecules to a target cell. Also, like ApoB-100, vitellogenin binds to a membrane receptor and enters the cell by endocytosis [12] . Computational (in silico) methods have been developed and widely applied to pharmacology hypothesis development and testing. These in silico methods include databases, quantitative structure-activity relationships, similarity searching, pharmacophores, homology models and other molecular modeling, machine learning, data mining, network analysis tools and data analysis tools that use a computer. Such methods have seen frequent use in the discovery and optimization of novel molecules with affinity to a target, the clarification of absorption, distribution, metabolism, excretion and toxicity properties as well as physicochemical characterization [19] . Our study involves the design of a suitable inhibitor molecule to bind to the vitellogenin domain and inhibit MTP and ApoB thereby resulting in potential decreased risk of cardiovascular diseases. By binding to ApoB may paralyze its cholesterol transport function. Bezafibrate is a drug shown to reduce the plasma cholesterol levels in many studies, similarly Miglustat an imino sugar; its treatment reduces lipid storage. Tea catechins [18, 7, 11] were identified by studies to be responsible for the cholesterol lowering function of green tea and therefore selected for this study. Canadine and berberine, plant alkaloids were identified as cholesterol lowering compounds [17] . Significant phytosterols [15, 21, 10, 4] gugglusterone, stanosterol, stigmastan, campestanol and campesterol have been previously studied and shown to have effects in lowering the level of cholesterol and therefore were selected for the designing of potential inhibitor molecules. Molecular docking studies were carried out to determine interactionsin order to provide a new insight to design novel molecules that can inhibit the function of the target. The computational analysis was carried out using Discovery Studio (DS) 2.5 (Accelrys Software Inc., San Diego; http://www.accelrys.com).
II. Materials And Methods
Cholesterol-related diseases have caused large number of deaths and therefore, in our study this issue has been addressed by designing potent inhibitors in order to help combat the rising health problems associated with cholesterol accumulation.The target APOB_HUMAN (P04114) was retrieved from UniProt [3] and its domains were analyzed in SMART [8] .The Lipoprotein N-terminal domain (LPD_N) was found from position 46-598 with an E-value of 6.97e-140. This represents a conserved region found in several lipid transport proteins, including vitellogenin, microsomal triglyceride transfer protein and Apolipoprotein B-100 [1] . The target ApoB is then modeled by homology modeling using CPHmodels-3.0 [14] with a Z-score = 59.41and validated in DS 2.5.The template chosen was 1LSH-the refined molecular structure of lipovitellin solved at 1.9 Å having an e-value of 5e-05 and 99% query coverage when a similarity search by protein-BLAST [20] against Protein Data Bank (PDB) [16] was conducted.
2.1Receptor -Ligands Preparation:
For the current study, bezafibrate, miglustat, canadine, berberine, catechin gallate, epigallocatechin gallate, guggulsterone, stanosterol, stigmastan, campestanol and campesterol were retrieved from PubChem [5] based on various literatures [15, 18, 7, 11, 21, 10, 4] substantiating their biological functionality. Furthermore, CHEMBL143610, CHEMBL141881, CHEMBL140786 and CHEMBL143821 from ZINC [9] database were retrieved for the corresponding target and were also used as scaffold molecules.The lead molecules were designed using ACD/ChemSketch Freeware. The modifications were not made to their functional group maintaining the molecules basic functionality. The 'General Purposes' protocol was used to calculate the molecular properties of the lead molecules to check if the compounds satisfy Lipinski's 'rule of 5'. The target ApoB-100 modeled structure was obtained and the site sphere (59.8562, 11.7025, 64.5437, 23) was defined for the binding site; typing was carried out by CHARMm forcefield (Momany-Rone parital charges methods) and followed by Conjugate Gradient minimization; until a constant potential energy is obtained. The screened compounds were typed similarly.
Virtual Screening:
The aforementioned library of compounds (approximately 222 compounds) was then subjected to Toxicity Prediction (TOPKAT) in the 'ADMET' protocol. NTP Carcinogenicity Call (Male Mouse) (v3.2), FDA Carcinogenicity Female Mouse Single vs Mult (v3.1), Developmental Toxicity Potential (DTP) (v3.1), Rat Oral LD50 (v3.1), Skin Irritation (v6.1) and Aerobic Biodegradabilty (v6.1), were the six criteria selected for the toxicity prediction. Further analysis by ADMET Descriptors in the 'ADMET' protocol was carried out to study the lead compounds pharmacokinetic properties.
Molecular Docking:
LibDock, a relatively fast algorithm that conducts 'HotSpots' matching of ligand conformations with rigid binding site's HotSpots map that is well-suited for large sized libraries [13] , was used to dock the target and ligands into the binding site. The resulting poses with higher LibDock score were investigated and the interacting residues were examined.
III. Results And Discussion
Out of the 222 lead compounds designed, most of them qualified Lipinski's 'rule of 5' (Molecular properties shown in Table 1 ) and their toxicities were studied. Male and Female Mouse Carcinogenicity and Aerobic Biodegradability models were primarily considered for the evaluation of toxicity level. Probability values from 0.0 to 0.30 are considered low probabilities,and are likely to produce a negative response in an experimentalassay; whereas probability values greater than 0.70 are consideredhigh, and are likely to produce a positive response in an experimental assay, probabilities greater than 0.30 but less than 0.70 are considered indeterminate (shown in Table 2 ). 14 lead molecules with low and intermediate probability values were further investigated for pharmacokinetic properties. The ADMET profiles of the 14 lead compounds are shown in Table  3 . Based on the drug-likeness and pharmacokinetic properties these lead molecules were selected for docking and the interactions were studied by docking simulations. The LibDock scores and the binding energies are shown in Table 4 . The lead SSr133-[(2E)-2-(3-hydroxycyclohexylidene)ethyl]nonanoic acidderived from stanosterol docked with the highest LibDock score of 121.359and CG383-(benzyloxy)-3,4-dihydro-2H-chromene-6-thiol derived from catechin gallate, docked with a score of 109.827. SSr13 (shown in Fig 1a) interacts with residues LYS209, PRO123 within the lipid transport domain by Intermolecular Hydrogen bonds (Fig 2a) and Bumps (Fig 2b) , respectively. CG38 (shown in Fig 1b) interacts with GLY93 by Intermolecular Hydrogen bonds (Fig 3) . These compounds have good absorption and high brain concentration/blood concentration level indicated in Fig 4a and 
IV. Discussion
Apolipoprotein B (ApoB) bind to lipid molecules such as cholesterol and triglycerides and transport them and it is primary constituent of chylomicrons and Low Density Lipoproteins that generally contribute to the bad cholesterol in the body leading to various heart diseases. Due this function they play a key role in cholesterol accumulation and have been selected for the current study. The compounds selected as scaffold were phytosterols (guggulsterone, campesterol, campestanol, stanosterol, and stigmastan), tea catechins ( cateching gallate and epigallocatechin gallate), alkaloids ( canadine and berberine) and FDA approved drug (bezafibrate and miglustat) compounds; all proven to reduce the levels of cholesterol.The lead compounds were predicted as non -carcinogenic, non -hepatotoxic, non -inhibitors of the CYPD26 enzyme with good absorption levels and aerobic biodegradability, thus indicating low risk of possible side effects. Molecular docking studies lead to the observation that SSr13 and CG38 bind with highest docking scores thereby indicating potential inhibition of the target ApoB-100 protein. The interacting residues of target, which form hydrogen bonds and bumps with the  compounds  are  ILE90  ,  GLU92,  GLY93,  ASN110,ILE111,VAL121,PRO123,  VAL137,  TYR138,LYS171,ARG208, 
V. Conclusion
Drug discovery process is multi-phased and involves preclinical and clinical trials. Computer aided approach is rapid and significant because it selects thelead molecules with good pharmacological and drug-like properties. ApoB-100 has important role in the utilization of cholesterol, triacylglycerols, and other lipids. The ApoB-containing lipoproteins depend on the microsomal tricylceride transfer protein (MTP) for its secretion. 14 small inhibitor molecules have been designed to bind to the LPD_N lipid transport domain.
Out of the 14 designed inhibitors, 3-[(2E)-2-(3-hydroxycyclohexylidene)ethyl] nonanoic acid (SSr13) designed from the scaffold molecule Stanosterol and 3-(benzyloxy)-3,4-dihydro-2H-chromene-6-thiol (CG38) derived from Catechin gallate was found to be the compounds with best docking scores. Furthermore, the interactions between SSr13 and LPD_Ndomain are more in number suggesting stronger and potentially effective binding. The interacting residues are within the lipid transport domain further substantiating the conclusion that SSr13 is the most potent inhibitor molecule designed to inhibit ApoB-100 and may potentially paralyze its cholesterol transport function.
This study could be a platform for facilitating further development of drugs that moderate cholesterol accumulation and thereby result in likelydecrease of the life threatening cardiacdiseases.
VI.
